- Home
- PHAT vs GCMG Comparison
PHAT vs GCMG Comparison
Compare PHAT & GCMG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAT
- GCMG
- Stock Information
- Founded
- PHAT 2018
- GCMG 1971
- Country
- PHAT United States
- GCMG United States
- Employees
- PHAT N/A
- GCMG N/A
- Industry
- PHAT Biotechnology: Pharmaceutical Preparations
- GCMG Finance/Investors Services
- Sector
- PHAT Health Care
- GCMG Finance
- Exchange
- PHAT Nasdaq
- GCMG Nasdaq
- Market Cap
- PHAT 727.5M
- GCMG 631.4M
- IPO Year
- PHAT 2019
- GCMG N/A
- Fundamental
- Price
- PHAT $9.45
- GCMG $11.72
- Analyst Decision
- PHAT Strong Buy
- GCMG Hold
- Analyst Count
- PHAT 5
- GCMG 5
- Target Price
- PHAT $16.40
- GCMG $13.60
- AVG Volume (30 Days)
- PHAT 1.7M
- GCMG 605.9K
- Earning Date
- PHAT 08-07-2025
- GCMG 08-07-2025
- Dividend Yield
- PHAT N/A
- GCMG 3.73%
- EPS Growth
- PHAT N/A
- GCMG N/A
- EPS
- PHAT N/A
- GCMG 0.14
- Revenue
- PHAT $81,859,000.00
- GCMG $530,455,000.00
- Revenue This Year
- PHAT $195.03
- GCMG $2.72
- Revenue Next Year
- PHAT $106.77
- GCMG $12.99
- P/E Ratio
- PHAT N/A
- GCMG $86.58
- Revenue Growth
- PHAT 3055.70
- GCMG 17.38
- 52 Week Low
- PHAT $2.21
- GCMG $10.04
- 52 Week High
- PHAT $19.71
- GCMG $14.48
- Technical
- Relative Strength Index (RSI)
- PHAT 60.80
- GCMG 45.66
- Support Level
- PHAT $8.19
- GCMG $11.50
- Resistance Level
- PHAT $9.76
- GCMG $11.72
- Average True Range (ATR)
- PHAT 0.66
- GCMG 0.23
- MACD
- PHAT -0.21
- GCMG 0.05
- Stochastic Oscillator
- PHAT 54.58
- GCMG 64.62
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
About GCMG GCM Grosvenor Inc.
GCM Grosvenor Inc is a world-wide alternative asset management firm. It invests on behalf of clients who seek allocations to alternative investments, such as private equity, infrastructure, real estate, credit, ESG and absolute return strategies. Company invest maximum in Private Equity. The company's offerings include multi-manager portfolios as well as portfolios of direct investments and co-investments.